JayanthiSivasothy(Sivasothy)LeaMDFACOG; FACS
Obstetrics & Gynecology • Dallas, TXGynecologic Oncology
UT Southwestern Medical Center
Dr. Lea is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2622
Summary
- Dr. Jayanthi Lea is the Division Chief of Gynecologic Oncology at University of Texas Southwestern Medical Center in Dallas, TX and is affiliated with multiple hospitals in the area, including University of Texas Southwestern Medical Center, and William P. Clements, Jr. University Hospitals and Parkland Health & Hospital System. She is an expert in ovarian, endometrial, cervical and vulvar cancer and is nationally recognized for her expertise in radical pelvic surgery and minimally invasive surgery. She received her medical degree from Brody School of Medicine at East Carolina University and has been in practice 21 years. She has more than 80 publications and over 500 citings.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Gynecologic Oncology, 2000 - 2004
U Texas Med Sch2004
OhioHealth/Riverside Methodist HospitalResidency, Obstetrics and Gynecology, 1996 - 2000
Brody School of Medicine at East Carolina UniversityClass of 1996
Certifications & Licensure
NC State Medical License 2008 - 2025
TX State Medical License 2000 - 2025
OH State Medical License 1997 - 2000- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
- FACSFellow
Awards, Honors, & Recognition
- Best Doctors 2022
- Best Doctors - Dallas 2022
- Texas Super Doctors 2022
- Join now to see all
Clinical Trials
- Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer Start of enrollment: 2008 May 01
- Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer Start of enrollment: 2012 Feb 01
- Randomized Phase II Study of Intravenous 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine® NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and S Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J Wilkinson, Emily M Whitman-Purves
Clinical Cancer Research. 2024-12-16 - 1 citationsCediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-...Jung-Min Lee, Mark F Brady, Austin Miller, Richard G Moore, Helen MacKay
Journal of Clinical Oncology. 2024-10-03 - RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells.Alexandra N Spirtos, Marwa W Aljardali, Sridevi Challa, Sneh Koul, Jayanthi S Lea
Biorxiv. 2024-09-05
Press Mentions
New Study Shows Increasing U.S. Cases of Uterine Cancer Overall and Higher Mortality in Black WomenJuly 25th, 2022- New Biomarkers and Flaw Found in Ovarian CancerAugust 3rd, 2021
Newly Developed Nanoparticle Vaccine Immunotherapy Targets Multiple Cancer TypesApril 25th, 2017- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- Tamil
External Links
- UT Southwesternhttp://profiles.utsouthwestern.edu/profile/45963/jayanthi-lea.html
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
